Stuart Therapeutics is a clinical-stage biopharmaceutical company based in Stuart, Fla., developing unique synthesized peptide therapeutics for ophthalmic diseases. Its platform, PolyCol™, is a synthesized peptide designed to repair and restore structural integrity and cell interaction domains in extracellular matrix (ECM) collagen. The company's lead candidate, ST-100, is a reparative therapeutic formulated as a topical drop for the treatment of dry eye disease and is the first drug candidate from the PolyCol platform. Stuart is pursuing variants of the PolyCol platform for additional ophthalmic indications, including glaucoma, dry and wet age-related macular degeneration, and neurotrophic keratitis. The company is led by President & CEO Eric Schlumpf. In March 2021 Stuart Therapeutics raised $11M in a Series A to fund development.

Total raised

$11M

Funding rounds

1

Latest round

Series A

Latest activity

Mar 2021